D

DaShenLin Pharmaceutical Group Co Ltd
SSE:603233

Watchlist Manager
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Watchlist
Price: 15.3 CNY -5.9% Market Closed
Market Cap: 17.4B CNY
Have any thoughts about
DaShenLin Pharmaceutical Group Co Ltd?
Write Note

DaShenLin Pharmaceutical Group Co Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

DaShenLin Pharmaceutical Group Co Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
D
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Research & Development
-ÂĄ86.4m
CAGR 3-Years
-102%
CAGR 5-Years
-139%
CAGR 10-Years
N/A
LBX Pharmacy Chain JSC
SSE:603883
Research & Development
-ÂĄ2.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yifeng Pharmacy Chain Co Ltd
SSE:603939
Research & Development
-ÂĄ40.6m
CAGR 3-Years
-59%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
Research & Development
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
Research & Development
-ÂĄ11.3m
CAGR 3-Years
-39%
CAGR 5-Years
-95%
CAGR 10-Years
N/A
A
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
Research & Development
-ÂĄ24.2m
CAGR 3-Years
-393%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

DaShenLin Pharmaceutical Group Co Ltd
Glance View

Market Cap
17.4B CNY
Industry
Retail

DaShenLin Pharmaceutical Group Co., Ltd. engages in the retail and wholesale of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong and currently employs 38,353 full-time employees. The company went IPO on 2017-07-31. The firm's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The firm mainly conducts its business within domestic market.

Intrinsic Value
44.52 CNY
Undervaluation 66%
Intrinsic Value
Price
D

See Also

What is DaShenLin Pharmaceutical Group Co Ltd's Research & Development?
Research & Development
-86.4m CNY

Based on the financial report for Jun 30, 2024, DaShenLin Pharmaceutical Group Co Ltd's Research & Development amounts to -86.4m CNY.

What is DaShenLin Pharmaceutical Group Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-139%

Over the last year, the Research & Development growth was -8%. The average annual Research & Development growth rates for DaShenLin Pharmaceutical Group Co Ltd have been -102% over the past three years , -139% over the past five years .

Back to Top